What is the new HIV regimen from Gilead and Merck?

It is a collaborative HIV treatment regimen developed by Gilead and Merck, with data to be presented at AIDS 2026.

What was Gilead's recent stock price?

Gilead shares closed at $130.28, with a YTD return of 7.1% and a one-year return of 21.3%.

Gilead and Merck to Present New HIV Data at AIDS 2026

Gilead Sciences plans to present new HIV research at AIDS 2026, including long-term results for lenacapavir and data on a collaborative regimen with Merck.

July 22, 2026

2 min read

Source: Simply Wall St.

Key Numbers

stock price

130.28

ytd return

7.1%

one year return

21.3%

Gilead Sciences (NasdaqGS:GILD) is set to present new HIV research data at the AIDS 2026 conference. The presentations will include long-term efficacy and safety results for lenacapavir, as well as data on a novel HIV treatment regimen developed in collaboration with Merck (NYSE:MRK).

Details

The clinical results will highlight the long-term effectiveness of lenacapavir, a long-acting injectable drug. Gilead will also share trial data for a combination regimen with Merck, aimed at expanding treatment options for patients.

Context

The announcement comes amid growing interest in long-acting HIV therapies, reinforcing Gilead's position in the field. The stock recently closed at $130.28, with a year-to-date return of 7.1% and a one-year return of 21.3%.

What This Means for Investors

Positive data could boost market confidence in Gilead's HIV portfolio and potentially lift the stock. The collaboration with Merck also broadens the R&D pipeline for both companies.

Frequently Asked Questions

Lenacapavir is a long-acting injectable drug for HIV treatment; Gilead will present its long-term efficacy and safety data.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.